Todd D. Sonoga @TrilogyUSA1

Investor/Consultant/Content Creator

Content is Information only & not recommendations Always consult a pro before making any investment decision.
#OTC #NASDAQ

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

ATTENTION #CEO
ONE-STOP-SHOP PROMO SERVICES
#SocialMediaSpecial
#podcastshow
#articles
#capital
#promovideos
#onestopshop
$BSTO $IGPK $DTII $RTON $HMLA $BIDCF
$SHOT $KOAN $VERB $NKPH $CTXR $CBGZF
$PLSH $RMRK $HIRU $KULR $DLOC $SOFI $IGOT $EGOX $AGFY $CBYN $PRST $CRDL $OPTI

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

A natural product intellectual property strategy begins well before a patent application is drafted. For a research-stage program, the central question is not whether an extract shows biological activity. It is whether the underlying material, active fraction, identified compound, supporting data, and development path can be defined with enough precision to create a defensible asset. https://t.co/5DkGI4MXiV

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Natural origin does not determine a product’s regulatory pathway. Intended use, claims, composition, route of administration, dose, manufacturing controls, and the totality of supporting evidence do. A regulatory strategy for natural products therefore begins well before a lead is presented as a development candidate. It begins when a complex source material is first defined, tracked, fractionated, and tested. https://t.co/fsj4qguhGk

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

How a Natural Product Discovery System Builds Evidence https://t.co/PpKrJZeqZr

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Natural materials present a compelling starting point for therapeutic research, but an extract is not a candidate. A natural product discovery system provides the disciplined pathway required to convert chemically complex, biologically relevant materials into evidence-supported development opportunities. Its purpose is not simply to find activity. It is to determine which observed activity is real, reproducible, attributable to defined chemical entities, and sufficiently differentiated to justify additional investment

https://t.co/0tcMPP7yMU

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Inc. Files U.S. Trademark Application for BlockR™, Advancing Anti-Inflammatory Development Program

https://t.co/eOpEsFmdGm

https://t.co/rL1RjUfoNN

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Inc. Files U.S. Trademark Application for BlockR™, Advancing Anti-Inflammatory Development Program

https://t.co/XMWzTaqXEp

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Inc. Files U.S. Trademark Application for BlockR™, Advancing Anti-Inflammatory Development Program

https://t.co/XMWzTaqXEp

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Regulatory Strategy for Natural Products https://t.co/E5rxngJigm

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Reproducibility in Natural Product Research https://t.co/Uyyl66kfBX

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Inc. Advances Intellectual Property Strategy Following Review of New Scientific Data

https://t.co/7zj0ijfpaC

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Sees Early International Partnering Interest Ahead of 2026 Asia Bio Partnering Forum https://t.co/U3gcGfYrHc via @ein_news

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

GenBio Inc. Advances Strategic Partnership Discussions as Asia-Pacific Biopharma Partnering Opens
ALISO VIEJO, CA, UNITED STATES, August 3, 2026 /EINPresswire.com/ — @GenBioUSA ., a biotechnology company focused on the discovery and development of novel therapeutics and natural bioactive technologies, today announced that it is participating in the opening of the Asia-Pacific partnering program, where biopharmaceutical companies, investors, research organizations, and strategic partners gather to explore new collaborations and commercialization opportunities.

With partnering activities now underway, GenBio is engaging with organizations seeking innovative scientific platforms, differentiated intellectual property, and strategic development opportunities across the biotechnology and pharmaceutical sectors
#BreakingNews

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

@GenBioUSA GenBio Inc. Advances Strategic Partnership Discussions as Asia-Pacific Biopharma Partnering Opens

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Locked & Loaded!

[Trilogy Marketing Strategies @TrilogyUSA1]

Emergent May Be The Most Undervalued In The Sector
Emergent Metals Just Already Several Bidders For Their Nevada Copper/Gold Prop
$EGMCF / $EMR 🇨🇦
Trading At A 75% Discount To Book Val
Current Market Cap Under $8M USD,The Sale Of This Property Could Bring In 4X Their Market Cap

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

$EGMCF GET IT ON YOUR RADAR NOW! COULD BE A BIG FINISH TO APRIL

[Trilogy Marketing Strategies @TrilogyUSA1]

Emergent Metals Corp OTCQB:EGMCF / EMR.V 🇨🇦
#GETSOME
@GrindStoneCapi1 @Stock_HighAlert @stewdomer @trader1sz @socialstartnow1 @T1F21 @DonnaWi08443185

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Lock it in!

[3 STOCKS A DAY @3Stocksaday]

IF $ASST HITS $2.50 BEFORE THE END OF THE YEAR, EVERYONE WHO SHARES AND LIKE THIS POST WILL GET A FREE MEMBERSHIP

[Todd D. Sonoga @TrilogyUSA1 @ipoguy]

Been Ahwile!
I'm back! $ASST $QTZM
Going long on both!

[Investor Network Press @investorNPress]

$NBBI CHART
https://t.co/9Qg39dANnS
#IHub_StockPosts #NDAQ #NASDAQ #AI #wsj #nytimes #business #reuters #forbes #jakepaul #cnn #bet #foxnews #latimes #Crainschicago #usatoday #barronsonline #IBDinvestors #yahoofinance #ESPN #WGN #Apple #Tsla #IR

[Trilogy Marketing Strategies @TrilogyUSA1]

Donny LOSES his shit and drops another #BOMB 💣
#Isreal and #Iran tell #DJT to eat a bag of #dicks!